{"id":7493,"date":"2024-03-22T10:35:00","date_gmt":"2024-03-22T08:35:00","guid":{"rendered":"https:\/\/www.msd.ch\/fr\/?post_type=news_item&#038;p=7493"},"modified":"2026-03-10T16:12:47","modified_gmt":"2026-03-10T14:12:47","slug":"swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte","status":"publish","type":"news_item","link":"https:\/\/www.msd.ch\/fr\/news\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\/","title":{"rendered":"Swissmedic autorise le pembrolizumab de MSD dans le traitement du m\u00e9lanome \u00e0 haut risque de stade pr\u00e9coce IIB\/IIC chez l\u2019adulte"},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[30],"class_list":["post-7493","news_item","type-news_item","status-publish","post-password-required","hentry","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Swissmedic autorise le pembrolizumab de MSD dans le traitement du m\u00e9lanome \u00e0 haut risque de stade pr\u00e9coce IIB\/IIC chez l\u2019adulte - msd.ch<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/fr\/news\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Swissmedic autorise le pembrolizumab de MSD dans le traitement du m\u00e9lanome \u00e0 haut risque de stade pr\u00e9coce IIB\/IIC chez l\u2019adulte - msd.ch\" \/>\n<meta property=\"og:description\" content=\"There is no excerpt because this is a protected post.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/fr\/news\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T14:12:47+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/news\\\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\\\/\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/news\\\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\\\/\",\"name\":\"Swissmedic autorise le pembrolizumab de MSD dans le traitement du m\u00e9lanome \u00e0 haut risque de stade pr\u00e9coce IIB\\\/IIC chez l\u2019adulte - msd.ch\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/#website\"},\"datePublished\":\"2024-03-22T08:35:00+00:00\",\"dateModified\":\"2026-03-10T14:12:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/news\\\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\\\/#breadcrumb\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/\",\"name\":\"msd.ch\",\"description\":\"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Swissmedic autorise le pembrolizumab de MSD dans le traitement du m\u00e9lanome \u00e0 haut risque de stade pr\u00e9coce IIB\/IIC chez l\u2019adulte - msd.ch","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/fr\/news\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\/","og_locale":"en_US","og_type":"article","og_title":"Swissmedic autorise le pembrolizumab de MSD dans le traitement du m\u00e9lanome \u00e0 haut risque de stade pr\u00e9coce IIB\/IIC chez l\u2019adulte - msd.ch","og_description":"There is no excerpt because this is a protected post.","og_url":"https:\/\/www.msd.ch\/fr\/news\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\/","og_site_name":"msd.ch","article_modified_time":"2026-03-10T14:12:47+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/fr\/news\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\/","url":"https:\/\/www.msd.ch\/fr\/news\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\/","name":"Swissmedic autorise le pembrolizumab de MSD dans le traitement du m\u00e9lanome \u00e0 haut risque de stade pr\u00e9coce IIB\/IIC chez l\u2019adulte - msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/fr\/#website"},"datePublished":"2024-03-22T08:35:00+00:00","dateModified":"2026-03-10T14:12:47+00:00","breadcrumb":{"@id":"https:\/\/www.msd.ch\/fr\/news\/swissmedic-autorise-le-pembrolizumab-de-msd-dans-le-traitement-du-melanome-a-haut-risque-de-stade-precoce-iib-iic-chez-ladulte\/#breadcrumb"},"inLanguage":"en-US"},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/fr\/#website","url":"https:\/\/www.msd.ch\/fr\/","name":"msd.ch","description":"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/7493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":43,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/7493\/revisions"}],"predecessor-version":[{"id":9126,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/7493\/revisions\/9126"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media?parent=7493"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/tags?post=7493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}